RxDoctor Payments Data

Rachel Brooks

Family · Toledo, OHNPI 1801220884

Payments from drug & device makers

$1,101in general payments, 2019–2025

Across 57 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$261
  • Biohaven Pharmaceuticals, Inc.$123
  • AbbVie$118
  • GSK$104
  • Biohaven Pharmaceutical Holding Company Ltd.$73
  • Pfizer$73
  • plus $349 from 8 others

What the payments were for

  • Food & beverage$1,08899%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,101 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$36,585
Medicare patients
110
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol137$105,406
JardianceEmpagliflozin75$84,211
MounjaroTirzepatide57$67,616
JanuviaSitagliptin Phosphate72$61,445
EliquisApixaban86$59,342
OzempicSemaglutide48$58,208
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr81$39,968
TradjentaLinagliptin63$39,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$29,636
Bydureon BciseExenatide Microspheres21$23,189
TrulicityDulaglutide18$21,798
XareltoRivaroxaban12$17,548
Breo ElliptaFluticasone/Vilanterol30$16,793
LinzessLinaclotide17$12,358
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$12,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat$67$141,964169 claims
AstraZenecaFarxiga, Symbicort$42$108,458148 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$104$86,397142 claims
PfizerEliquis$73$59,34286 claims
AbbVieLinzess, Savella$118$19,36828 claims
BayerKerendia$55$9,23215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.

Other family in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →